Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):310–316. doi: 10.1097/QAI.0b013e31826ebb5c

Table 2.

PK parameters for EFV after administration of EFV alone and in combination with AL (Coartem®).

EFV
GM; 90%CI		 EFV + AL
GM; 90%CI		 Change
% (p-value), n
Cmax (µg/mL) 4.06 (3.58 to 4.92) 3.69 (3.26 to 4.64) −9 (0.622), 12
Tmax (hr) 4.0 (2.0 to 6.0) 2.0 (2.0 to 3.5)
AUC0–24 (hr•µg/mL) 56.9 (49.0 to 72.7) 47.2 (39.5 to 68.0) −17 (0.034), 12
t1/2 (hr) 22.4 (16.5 to 35.9) 17.1 (12.6 to 35.1) −24 (0.083), 11

Note: CI, confidence intervals; GM, geometric means; Tmax and t1/2 presented as median (P25, P75). Wilcoxon signed-rank test with 2-tailed distribution was used for p-value calculation.